责任驱动创新中药普惠！以岭药业获ESG新标杆企业奖

Group 1 - The core viewpoint of the article highlights Yiling Pharmaceutical's recognition as an "ESG New Benchmark Enterprise" for its systematic practices and innovative achievements in the ESG field [1][4] - Yiling Pharmaceutical is committed to social responsibility and aims to promote the harmonious coexistence of enterprises with society and the environment through a unique ESG practice path [1][4] Group 2 - Yiling Pharmaceutical adheres to the principle of "inheritance and innovation for the benefit of humanity," focusing on the theory of network diseases and clinical needs to promote the accessibility of traditional Chinese medicine [1][3] - As of the end of 2024, Yiling Pharmaceutical has launched 17 innovative patented traditional Chinese medicines, with 11 included in the national medical insurance catalog and 5 in the national essential drug catalog [1][3] Group 3 - The company is addressing the challenge of rare disease treatment by focusing on improving the accessibility of rare disease drugs, exemplified by its clinical trial for the innovative drug Canrong Granules for ALS [3] - Yiling Pharmaceutical emphasizes high-quality source control and rural revitalization by establishing traditional Chinese medicine material cultivation bases that meet high standards [3] Group 4 - The "ESG New Benchmark Enterprise Award" is a prestigious recognition aimed at companies excelling in low-carbon transformation, social responsibility, and compliance governance, with Yiling Pharmaceutical being acknowledged for its long-term commitment to sustainable development [4]